Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 11/2014

01-11-2014 | Research Article

miR-152 suppresses gastric cancer cell proliferation and motility by targeting CD151

Authors: Ronglin Zhai, Xuefeng Kan, Bo Wang, Hansong Du, Yueping Long, Heshui Wu, Kaixiong Tao, Guobin Wang, Lihong Bao, Fen Li, Wanli Zhang

Published in: Tumor Biology | Issue 11/2014

Login to get access

Abstract

We aimed to study the post-translational regulation of CD151 by the microRNA miR-152. CD151 is highly expressed in gastric cancer (GC) and has been shown to accelerate GC by enhancing invasion and metastasis; however, its regulation is still unclear. Our results showed decreased expression of miR-152 in GC tissue samples and cell lines. In addition, miR-152 complementation significantly inhibits both the proliferation and motility of GC cells. CD151 was found to be a target of miR-152, and overexpression of CD151 attenuated the suppressive effect of miR-152. Our findings highlight an essential role of miR-152 in the regulation of proliferation and motility of GC cells and suggest a potential application of miR-152 in GC treatment.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Wang YY, Ye ZY, Zhao ZS, Tao HQ, Li SG. Systems biology approach to identification of biomarkers for metastatic progression in gastric cancer. J Cancer Res Clin Oncol. 2010;136:135–41.PubMedCrossRef
3.
Otani K, Li X, Arakawa T, Chan FK, Yu J. Epigenetic-mediated tumor suppressor genes as diagnostic or prognostic biomarkers in gastric cancer. Expert Rev Mol Diagn. 2013;13:445–55.PubMedCrossRef
4.
5.
Pols MS, Klumperman J. Trafficking and function of the tetraspanin cd63. Exp Cell Res. 2009;315:1584–92.PubMedCrossRef
6.
Sadej R, Romanska H, Kavanagh D, Baldwin G, Takahashi T, Kalia N, et al. Tetraspanin cd151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res. 2010;70:6059–70.PubMedCrossRef
7.
Kwon MJ, Seo J, Kim YJ, Choi JY, Kim TE, Lee DH, et al. Prognostic significance of cd151 overexpression in non-small cell lung cancer. Lung Cancer. 2013;81:109–16.PubMedCrossRef
8.
Yang YM, Zhang ZW, Liu QM, Sun YF, Yu JR, Xu WX. Overexpression of cd151 predicts prognosis in patients with resected gastric cancer. PLoS One. 2013;8:e58990.PubMedCentralPubMedCrossRef
9.
Zhang N, Wei X, Xu L. Mir-150 promotes the proliferation of lung cancer cells by targeting p53. FEBS Lett. 2013;587:2346.PubMedCrossRef
10.
Ayaz L, Gorur A, Yaroglu HY, Ozcan C, Tamer L. Differential expression of micrornas in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma. J Cancer Res Clin Oncol. 2013;139:1499.PubMedCrossRef
11.
Wach S, Nolte E, Theil A, Stohr C, Rau TT, Hartmann A, et al. Microrna profiles classify papillary renal cell carcinoma subtypes. Br J Cancer. 2013;109:714.PubMedCentralPubMedCrossRef
12.
Chen J, Yao D, Li Y, Chen H, He C, Ding N, et al. Serum microrna expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med. 2013;32:557.PubMedCentralPubMed
13.
Chang L, Guo F, Wang Y, Lv Y, Huo B, Wang L, et al. Microrna-200c regulates the sensitivity of chemotherapy of gastric cancer sgc7901/ddp cells by directly targeting rhoe. Pathol Oncol Res. 2013;20:93.PubMedCrossRef
14.
Jiang B, Li Z, Zhang W, Wang H, Zhi X, Feng J, et al. Mir-874 inhibits cell proliferation, migration and invasion through targeting aquaporin-3 in gastric cancer. J Gastroenterol. 2013;49:1011.PubMedCrossRef
15.
Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, et al. Altered expression of mir-148a and mir-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg. 2010;14:1170–9.PubMedCrossRef
16.
Huang J, Wang Y, Guo Y, Sun S. Down-regulated microrna-152 induces aberrant DNA methylation in hepatitis b virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology. 2010;52:60–70.PubMedCrossRef
17.
Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L, et al. Mir-152 controls migration and invasive potential by targeting TGFalpha in prostate cancer cell lines. Prostate. 2013;73:1082–9.PubMedCrossRef
18.
Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, et al. Mir-152 and mir-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting dnmt1 directly: a novel epigenetic therapy independent of decitabine. Oncogene. 2013;33:378.PubMedCrossRef
19.
Hemler ME. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol. 2005;6:801–11.PubMedCrossRef
20.
Han ZB, Yang Z, Chi Y, Zhang L, Wang Y, Ji Y, et al. Microrna-124 suppresses breast cancer cell growth and motility by targeting cd151. Cell Physiol Biochem. 2013;31:823–32.PubMedCrossRef
21.
Fei Y, Wang J, Liu W, Zuo H, Qin J, Wang D, et al. Cd151 promotes cancer cell metastasis via integrins alpha3beta1 and alpha6beta1 in vitro. Mol Med Rep. 2012;6:1226–30.PubMed
22.
Metadata
Title
miR-152 suppresses gastric cancer cell proliferation and motility by targeting CD151
Authors
Ronglin Zhai
Xuefeng Kan
Bo Wang
Hansong Du
Yueping Long
Heshui Wu
Kaixiong Tao
Guobin Wang
Lihong Bao
Fen Li
Wanli Zhang
Publication date
01-11-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2471-2

Other articles of this Issue 11/2014

Tumor Biology 11/2014 Go to the issue

Research Article

Matrix metalloproteinase-7 mRNA and protein expression in gastric carcinoma: a meta-analysis

Research Article

Nonoccupational physical activity and risk of ovarian cancer: a meta-analysis

Research Article

Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer

Review

Role of microRNA-93 in regulation of angiogenesis

Research Article

Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro

Review

SOCS6 is a selective suppressor of receptor tyrosine kinase signaling
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits